Monthly High-Dose Vitamin D Supplementation and Cancer Risk: A Post Hoc Analysis of the Vitamin D Assessment Randomized Clinical Trial
Scragg R, Khaw KT, Toop L, Sluyter J, Lawes CMM, Waayer D, Giovannucci E, Camargo CA
JAMA oncology · 124 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- Cancer Research UK
- Gobierno
- National Institute for Health and Care Research
- Gobierno
- Medical Research Council
- Gobierno
- Health Research Council of New Zealand
- Gobierno
- National Institute for Health Research (NIHR)
- Subvenciones
- Cancer Research UK (14136); National Institute for Health and Care Research (NF-SI-0512-10114); Medical Research Council (MR/N003284/1)
Según 5 financiadores declarados.
Publicación
- Publicado
- 2018-07-20 · JAMA Oncol · vol. 4 · número 11 · pág. e182178
- Editorial
- American Medical Association
- Citado
- 168 citas · más que el 100% de estudios similares · 15.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 36 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Vitamin D Research Studies · Nutritional Studies and Diet · Global Cancer Incidence and Screening
- Palabras clave
- vitamin D supplementation, vitamin D3, cancer incidence, cancer mortality, cancer prevention, high-dose vitamin D, 25-hydroxyvitamin D, older adults, non-melanoma skin cancer, post hoc analysis, randomized controlled trials, community-dwelling adults, New Zealand population, vitamin D deficiency, postmenopausal women
- MeSH
- humans, neoplasms, vitamin d, incidence, double-blind method, time factors, dietary supplements, aged, aged, 80 and over, middle aged, female, male
8 autores
- Robert K.R. Scragg🇳🇿 · autor de correspondenciaUniversity of Auckland
- Kay‐Tee Khaw🇬🇧University of Cambridge
- Les J Toop🇳🇿University of Otago
- John Sluyter🇳🇿University of Auckland
- Carlene M.M. Lawes🇳🇿University of Auckland
- Debbie Waayer🇳🇿University of Auckland
- Edward L. Giovannucci🇺🇸Harvard University
- Carlos A. Camargo🇺🇸Harvard University; Massachusetts General Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Importance
Previous randomized clinical trials have reported inconsistent results on the effect of vitamin D supplementation on cancer incidence.
Objective
To examine whether high-dose vitamin D supplementation received monthly, without calcium, is associated with a reduction in cancer incidence and cancer mortality in the general population.
Design, setting, and participants
This is a post hoc analysis of data from the Vitamin D Assessment (ViDA) study, a randomized, double-blind, placebo-controlled trial that recruited participants from family practices and community groups in Auckland, New Zealand, from April 5, 2011, through November 6, 2012, with follow-up completed December 31, 2015. Participants were adult community residents aged 50 to 84 years. Of 47 905 adults invited from family practices and 163 from community groups, 5110 participants were randomized to receive vitamin D3 (n = 2558) or placebo (n = 2552). Two participants withdrew consent, and all others (n = 5108) were included in the primary analysis. Data analysis was by intention to treat.
Interventions
Oral vitamin D3, in an initial bolus dose of 200 000 IU and followed by monthly doses of 100 000 IU, or placebo for a median of 3.3 years (range, 2.5-4.2 years).
Main outcomes and measures
Post hoc primary outcome was the number of all primary invasive and in situ malignant neoplasms (excluding nonmelanoma skin cancers) diagnosed from randomization until the study medication was discontinued on July 31, 2015.
Results
Of the 5108 participants included in the analysis, the mean (SD) age was 65.9 (8.3) years, 58.1% were male, and 4253 (83.3%) were of European or another race/ethnicity, with the remainder being Polynesian or South Asian. Mean (SD) baseline deseasonalized 25-hydroxyvitamin D concentration was 26.5 (9.0) ng/mL. In a random sample of 438 participants, the mean follow-up 25-hydroxyvitamin D concentration consistently was greater than 20 ng/mL higher in the vitamin D group than in the placebo group. The primary outcome of cancer comprised 328 total cases of cancer (259 invasive and 69 in situ malignant neoplasms) and occurred in 165 of 2558 participants (6.5%) in the vitamin D group and 163 of 2550 (6.4%) in the placebo group, yielding an adjusted hazard ratio of 1.01 (95% CI, 0.81-1.25; P = .95).
Conclusions and relevance
High-dose vitamin D supplementation prescribed monthly for up to 4 years without calcium may not prevent cancer. This study suggests that daily or weekly dosing for a longer period may require further study.
Trial registration
anzctr.org.au Identifier: ACTRN12611000402943.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.